ID: ALA5176043

Max Phase: Preclinical

Molecular Formula: C19H19N5O3

Molecular Weight: 365.39

Representations

Canonical SMILES:  CCNC(=O)c1cnc(-c2cncc(Oc3ncccc3OCC)c2)nc1

Standard InChI:  InChI=1S/C19H19N5O3/c1-3-21-18(25)14-10-23-17(24-11-14)13-8-15(12-20-9-13)27-19-16(26-4-2)6-5-7-22-19/h5-12H,3-4H2,1-2H3,(H,21,25)

Standard InChI Key:  GDVFYAPTMWNIKT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 365.39

Molecular Weight (Monoisotopic): 365.1488

AlogP: 2.87

#Rotatable Bonds: 7

Polar Surface Area: 99.12

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.09

CX Basic pKa: 3.23

CX LogP: 1.53

CX LogD: 1.53

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.69

Np Likeness Score: -1.59

References

1. Futatsugi K, Cabral S, Kung DW, Huard K, Lee E, Boehm M, Bauman J, Clark RW, Coffey SB, Crowley C, Dechert-Schmitt AM, Dowling MS, Dullea R, Gosset JR, Kalgutkar AS, Kou K, Li Q, Lian Y, Loria PM, Londregan AT, Niosi M, Orozco C, Pettersen JC, Pfefferkorn JA, Polivkova J, Ross TT, Sharma R, Stock IA, Tesz G, Wisniewska H, Goodwin B, Price DA..  (2022)  Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.,  65  (22.0): [PMID:36322383] [10.1021/acs.jmedchem.2c01200]

Source

Source(1):

• Scientific Literature